Endo International PLC (NASDAQ:ENDP) (TSE:ENL) had its price objective lowered by research analysts at Citigroup Inc. from $9.00 to $7.00 in a report released on Friday. The brokerage presently has a “neutral” rating on the stock. Citigroup Inc.’s price target would indicate a potential upside of 1.01% from the company’s previous close.

A number of other equities research analysts have also commented on the stock. Oppenheimer Holdings, Inc. reaffirmed a “hold” rating on shares of Endo International PLC in a research note on Sunday, July 23rd. ValuEngine lowered shares of Endo International PLC from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Zacks Investment Research raised shares of Endo International PLC from a “hold” rating to a “buy” rating and set a $9.75 price objective on the stock in a research note on Wednesday, October 11th. Royal Bank Of Canada set a $9.00 price objective on shares of Endo International PLC and gave the company a “hold” rating in a research note on Tuesday, October 17th. Finally, BidaskClub raised shares of Endo International PLC from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. Four research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and five have assigned a buy rating to the stock. The company currently has an average rating of “Hold” and an average target price of $11.67.

Endo International PLC (ENDP) traded up $0.84 on Friday, reaching $6.93. 12,136,900 shares of the company’s stock were exchanged, compared to its average volume of 7,342,927. Endo International PLC has a 52-week low of $5.77 and a 52-week high of $18.63. The company has a quick ratio of 0.86, a current ratio of 1.08 and a debt-to-equity ratio of 10.78. The company has a market cap of $1,550.00, a price-to-earnings ratio of 1.43 and a beta of 0.53.

Endo International PLC (NASDAQ:ENDP) (TSE:ENL) last posted its earnings results on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.06. Endo International PLC had a negative net margin of 126.97% and a positive return on equity of 66.98%. The firm had revenue of $786.90 million for the quarter, compared to analyst estimates of $794.93 million. During the same period in the previous year, the firm posted $1.01 EPS. The company’s revenue for the quarter was down 11.0% compared to the same quarter last year. research analysts expect that Endo International PLC will post 3.54 EPS for the current fiscal year.

WARNING: “Endo International PLC (ENDP) PT Lowered to $7.00” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The correct version of this report can be read at https://www.watchlistnews.com/endo-international-plc-endp-pt-lowered-to-7-00/1701057.html.

In other Endo International PLC news, CFO Blaise Coleman acquired 6,500 shares of the stock in a transaction on Tuesday, August 15th. The shares were purchased at an average price of $7.89 per share, for a total transaction of $51,285.00. Following the completion of the acquisition, the chief financial officer now owns 13,729 shares in the company, valued at approximately $108,321.81. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Corporate insiders own 0.50% of the company’s stock.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. LMR Partners LLP acquired a new position in Endo International PLC during the third quarter worth $148,000. Van ECK Associates Corp raised its holdings in Endo International PLC by 67.1% during the third quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock worth $2,921,000 after buying an additional 136,873 shares during the last quarter. Alps Advisors Inc. raised its holdings in shares of Endo International PLC by 9.3% in the third quarter. Alps Advisors Inc. now owns 250,511 shares of the company’s stock valued at $2,146,000 after purchasing an additional 21,373 shares during the last quarter. Gamco Investors INC. ET AL raised its holdings in shares of Endo International PLC by 76.2% in the third quarter. Gamco Investors INC. ET AL now owns 110,500 shares of the company’s stock valued at $946,000 after purchasing an additional 47,800 shares during the last quarter. Finally, Crossmark Global Holdings Inc. purchased a new stake in shares of Endo International PLC in the third quarter valued at about $293,000. Hedge funds and other institutional investors own 90.50% of the company’s stock.

About Endo International PLC

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Analyst Recommendations for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.